Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891069 | 0.83 | FAP (0.37) | TSHR | |
| SCHEMBL9891070 | 0.81 | FAP (0.34) | — | |
| SCHEMBL23111121 | 0.78 | FAP (0.33) | — | |
| SCHEMBL11315336 | 0.76 | LPAR3 (0.52) | LPAR3LPAR1LPAR2TSHRLPAR5 | |
| SCHEMBL30417324 | 0.75 | LPAR3 (0.42) | P2RY10LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL24942201 | 0.75 | LMNA (0.49) | PLA2G2CTSHRLMNACES2 | |
| SCHEMBL776818 | 0.74 | LPAR3 (0.48) | LPAR3LPAR1LPAR2TSHRLMNA | |
| SCHEMBL23089026 | 0.74 | FGFR1 (0.33) | P2RY10 | |
| SCHEMBL27718749 | 0.72 | LPAR3 (0.47) | LPAR3LPAR1LPAR2TSHRLMNA | |
| SCHEMBL776772 | 0.70 | CYP3A4 (0.52) | LPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603380-B2 | Antiviral acyclonucleoside analogues for use in treating a viral infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-03-14 | — | — | US | disclosed |
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | NEOVIRTECH (FR) | 2021-03-18 | — | — | US | disclosed |
| EP-3784680-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | Centre national de la recherche scientifique (FR) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603380-B2 | Antiviral acyclonucleoside analogues for use in treating a viral infection | TYMP, EIF2AK2, ENTPD5 | P2RY10 514/4885PLA2G2C 3764/4885LPAR3 2542/4885 |
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | TYMP, EIF2AK2, PNP | P2RY10 630/4885PLA2G2C 2829/4885LPAR3 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.